🎉 M&A multiples are live!
Check it out!

CSL Valuation Multiples

Discover revenue and EBITDA valuation multiples for CSL and similar public comparables like Julphar, Vivoryon Therapeutics, and Galapagos.

CSL Overview

About CSL

CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world’s second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.


Founded

1991

HQ

Australia
Employees

32K+

Website

csl.com

Financials

LTM Revenue $24.1B

LTM EBITDA $8.0B

EV

$87.1B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

CSL Financials

CSL has a last 12-month revenue of $24.1B and a last 12-month EBITDA of $8.0B.

In the most recent fiscal year, CSL achieved revenue of $9.3B and an EBITDA of $3.0B.

CSL expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See CSL valuation multiples based on analyst estimates

CSL P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $8.3B $9.3B XXX XXX XXX
Gross Profit $3.6B $4.2B XXX XXX XXX
Gross Margin 43% 46% XXX XXX XXX
EBITDA $2.5B $3.0B XXX XXX XXX
EBITDA Margin 30% 32% XXX XXX XXX
Net Profit $1.4B $1.4B XXX XXX XXX
Net Margin 17% 15% XXX XXX XXX
Net Debt n/a $5.7B XXX XXX XXX

Financial data powered by Morningstar, Inc.

CSL Stock Performance

As of March 14, 2025, CSL's stock price is AUD 250 (or $158).

CSL has current market cap of AUD 121B (or $76.6B), and EV of AUD 138B (or $87.1B).

See CSL trading valuation data

CSL Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$87.1B $76.6B XXX XXX XXX XXX $6.30

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

CSL Valuation Multiples

As of March 14, 2025, CSL has market cap of $76.6B and EV of $87.1B.

CSL's trades at 5.7x LTM EV/Revenue multiple, and 17.1x LTM EBITDA.

Analysts estimate CSL's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for CSL and 10K+ public comps

CSL Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $87.1B XXX XXX XXX
EV/Revenue 7.0x XXX XXX XXX
EV/EBITDA 21.1x XXX XXX XXX
P/E 31.6x XXX XXX XXX
P/E/Growth 1.2x XXX XXX XXX
EV/FCF 48.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get CSL Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

CSL Valuation Multiples

CSL's NTM/LTM revenue growth is 7%

CSL's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Over next 12 months, CSL's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate CSL's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for CSL and other 10K+ public comps

CSL Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 12% XXX XXX XXX XXX
EBITDA Margin 33% XXX XXX XXX XXX
EBITDA Growth 21% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 40% XXX XXX XXX XXX
Revenue per Employee $0.3M XXX XXX XXX XXX
Opex per Employee $0.1M XXX XXX XXX XXX
S&M Expenses to Revenue 11% XXX XXX XXX XXX
G&A Expenses to Revenue 6% XXX XXX XXX XXX
R&D Expenses to Revenue 10% XXX XXX XXX XXX
Opex to Revenue 33% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

CSL Public Comps

See public comps and valuation multiples for Biopharmaceuticals and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
Armata Pharmaceuticals XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

CSL M&A and Investment Activity

CSL acquired  XXX companies to date.

Last acquisition by CSL was  XXXXXXXX, XXXXX XXXXX XXXXXX . CSL acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by CSL

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About CSL

When was CSL founded? CSL was founded in 1991.
Where is CSL headquartered? CSL is headquartered in Australia.
How many employees does CSL have? As of today, CSL has 32K+ employees.
Who is the CEO of CSL? CSL's CEO is Dr. Paul McKenzie.
Is CSL publicy listed? Yes, CSL is a public company listed on ASX.
What is the stock symbol of CSL? CSL trades under CSL ticker.
When did CSL go public? CSL went public in 1994.
Who are competitors of CSL? Similar companies to CSL include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics.
What is the current market cap of CSL? CSL's current market cap is $76.6B
What is the current revenue of CSL? CSL's last 12-month revenue is $24.1B.
What is the current EBITDA of CSL? CSL's last 12-month EBITDA is $8.0B.
What is the current EV/Revenue multiple of CSL? Current revenue multiple of CSL is 5.7x.
What is the current EV/EBITDA multiple of CSL? Current EBITDA multiple of CSL is 17.1x.
What is the current revenue growth of CSL? CSL revenue growth between 2023 and 2024 was 12%.
Is CSL profitable? Yes, CSL is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.